We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | 장 마감 후 (AMC) | $10.85 | — | — | $3.81B | — | 예정 |
| FY2026 Q1 | 2026. 04. 29. | 시각 미정 | — | $7.27 | — | — | $3.03B | 보고됨 |
| FY2025 Q3 | 2025. 10. 28. | 시각 미정 | — | $30.23 | — | — | $10.41B |
Consensus PT $833.31 · 28 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 19. | Canaccord Genuity | — | 의견 유지 | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 05. 19. | BMO Capital | — | 의견 유지 | Outperform → Outperform | — | BMO Capital: Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
내부자 거래(Form 4) 신고가 제출되었습니다.
| 보고됨 |
| FY2025 Q2 | 2025. 08. 01. | 시각 미정 | — | $18.68 | — | — | $6.69B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 812,236 | $627.57B | 0.54% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 281,151 | $217.01B | 0.34% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Stored first · Google News · Yahoo Finance (English)
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? Yahoo Finance
National Pension Service Acquires 82,853 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
National Pension Service Acquires 82,853 Shares of Regeneron Pharmaceuticals, Inc. $REGN MarketBeat
Regeneron Pharmaceuticals (REGN) Receives WHO Approval for Ebola Treatment - GuruFocus
Regeneron Pharmaceuticals (REGN) Receives WHO Approval for Ebola Treatment GuruFocus
Regeneron (REGN) Advances Maftivimab for Ebola Treatment Trials - GuruFocus
Regeneron (REGN) Advances Maftivimab for Ebola Treatment Trials GuruFocus